Compare Quanta Services Inc (PWR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Recursion Pharmaceuticals Inc — how do they compare? Quanta Services Inc trades at $625.61 (market cap $96.08B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Quanta Services Inc is far larger — about 51.7× Recursion Pharmaceuticals Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PWR | RXRX | |
|---|---|---|
Market Cap | $96.08B | $1.86B |
Sector | Industrials | Health |
52-Week High | $785.24 | $6.79 |
52-Week Low | $376.01 | $2.84 |
Enterprise Value | $102.17B | $1.38B |
Dividend Yield | 0.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quanta Services (PWR) trades at $639.05, up 2.34% with strong technical momentum and bullish sentiment. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, supported by a record $53B backlog. Recent Q2 2026 earnings beat expectations with EPS of $4.24 versus $3.31 expected, while analyst consensus remains strongly bullish with a $811.14 price target.
PWR presents compelling growth potential driven by infrastructure demand and AI-related projects, though elevated valuation multiples (P/E 73.12) and significant capital expenditures pose risks. The company's strong backlog and margin expansion support upside, but investors should monitor execution on large-scale projects and competitive pressures in the construction sector.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
